Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial

McDonald CM, Villa C, Soslow JH, Maharry K, Hogan N, Binks M, Berth KC, Elliott KA, Taylor M, Hor KN, Signorovich J, Henricson EK, Phan HC, Apkon S, Ghosh PS, Tian C, Veerapandiyan A, Ramos-Platt L, Gambetta K, Bernes SM, Varadhachary AS, Iannaccone ST, Laverty CG, Perlman SJ, Bass NE, Mosher K, Butterfield RJ, Mathews KD, Scharf RJ, Smith EC, Emerson JA, Mercuri E, Awadalla MS, Marbán L, Marbán E; HOPE-3 Investigators. Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026 Jul 29:S0140-6736(26)01385-1. doi: 10.1016/S0140-6736(26)01385-1. Epub ahead of print. PMID: 42526472.


Related Posts